Pediatrix Medical Group Hits New 52-Week High of $18.21

Pediatrix Medical Group, Inc. has reached a significant milestone by hitting a new 52-week high of USD 18.21 on October 7, 2025. This achievement underscores the company's robust performance in the Pharmaceuticals & Biotechnology sector, where it has demonstrated a remarkable one-year return of 154.7%, significantly outpacing the S&P 500's return of 17.2%.
With a market capitalization of USD 1,476 million, Pediatrix operates as a small-cap company, showcasing a price-to-earnings (P/E) ratio of 8.00. The company has maintained a solid return on equity of 18.01%, indicating effective management of shareholder funds. Additionally, its debt-to-equity ratio stands at 0.33, reflecting a conservative approach to leverage.

Pediatrix's financial health is further highlighted by its impressive operating cash flow, which reached USD 244.56 million, and a high interest coverage ratio of 755.9. The stock's price-to-book ratio of 1.77 suggests it is trading at a reasonable valuation compared to its peers. Overall, the recent price movement and strong financial metrics position Pediatrix Medical Group favorably within its industry.